Semaglutide vs. Tirzepatide: a 36-week head-to-head.
Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.
The simple answer is not the useful answer. Tirzepatide tends to produce larger mean weight-loss numbers, while semaglutide has longer real-world familiarity and a deep cardiovascular-outcomes conversation around it.
What the averages hide
Responder curves matter. Averages do not tell you who discontinued, who needed dose pauses, or who lost lean mass because nutrition and resistance training were treated as optional.
The practical call
For a patient deciding with a clinician, the better question is not which drug wins a headline. It is which mechanism, dose path, monitoring plan, and cost reality can be sustained safely.
Medical note
This review is for education only and is not medical advice. Treatment decisions should be made with a licensed clinician who knows your history, medications, labs, and goals.